As this study concerned anticancer drugs that are either used in clinical practice or undergoing clinical trials across various types of cancer, not specifically targeting HCC, future screens tailored specifically toward HCC may result in additional candidate drugs with enhanced efficacy for HCC tumours with CYP2D6 deficiency. This evidence concerns the gene CYP2D6 and cancer.